ID   Hu609
AC   CVCL_8240
SY   HU609; Hu 609; HU 609
DR   BioSample; SAMN03151802
DR   Lonza; 245
DR   Wikidata; Q54896703
RX   PubMed=3708594;
RX   PubMed=3800330;
RX   PubMed=6546195;
RX   PubMed=7262169;
RX   PubMed=7905254;
RX   PubMed=8105864;
RX   PubMed=20143388;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v11_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a J82 derivative (PubMed=7905254; PubMed=20143388). Originally thought to originate from the histologically normal ureter of a female patient with clear cell renal carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00131.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (from parent cell line).
ST   Source(s): PubMed=11416159
ST   Amelogenin: X,Y
ST   D18S51: 10,12
ST   D21S11: 30,31
ST   D8S1179: 8,13
ST   FGA: 20,24
ST   TH01: 9.3
ST   vWA: 17,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0359 ! J82
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 23
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=3800330;
RA   Debiec-Rychter M., Christensen B., Kieler J., Wang C.Y.;
RT   "Chromosomal characterization and isoenzyme pattern of non-malignant
RT   and malignant human urothelial cell lines.";
RL   Anticancer Res. 6:1237-1244(1986).
//
RX   PubMed=6546195; DOI=10.1007/BF00121494;
RA   Schroyens W., Mareel M.M., Dragonetti C.;
RT   "In vitro invasiveness of human bladder cancer from cell lines and
RT   biopsy specimens.";
RL   Clin. Exp. Metastasis 1:153-162(1983).
//
RX   PubMed=7262169; DOI=10.1016/0014-2964(81)90123-7;
RA   Vilien M., Wolf H., Rasmussen F.;
RT   "Immunological characterization of cell lines establishing from
RT   malignant and normal human urothelium.";
RL   Eur. J. Cancer 17:321-327(1981).
//
RX   PubMed=7905254;
RA   Christensen B., Hansen C., Kieler J., Schmidt J.;
RT   "Identity of non-malignant human urothelial cell lines classified as
RT   transformation grade I (TGrI) and II (TGrII).";
RL   Anticancer Res. 13:2187-2191(1993).
//
RX   PubMed=8105864; DOI=10.1038/bjc.1993.449;
RA   Christensen B., Hansen C., Debiec-Rychter M., Kieler J., Ottensen S.,
RA   Schmidt J.;
RT   "Identity of tumorigenic human urothelial cell lines and
RT   'spontaneously' transformed sublines.";
RL   Br. J. Cancer 68:879-884(1993).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//